Answers are grounded in this paper and cite their sources.
Dasatinib induces hematologic and cytogenetic responses in patients with CML or Ph-positive ALL who cannot tolerate or are resistant to imatinib. (ClinicalTrials.gov number, NCT00064233 [ClinicalTrials.gov].).
No takes yet. Share an insight, caveat, or question.
Talpaz et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: